Breathe Well Live Well
 CBS News |
H-P results, job cuts expected after hours
MarketWatch Joining NetApp in the red were shares of MediciNova Inc. (US:MNOV) after the biopharma company said a clinical study of its MN-221 asthma treatment didn't yield statistically significant results. The shares fell 47% to $1.46 in modest volume. US HOT STOCKS: Hewlett-Packard, Pandora, NetApp Active In Late Trading -1- |
View full post on asthma – Google News
|
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma …
MarketWatch (press release) MediciNova intends to design pivotal trial(s) that will include technological and operational improvements and further controls for medications that are not typically used in the treatment of acute exacerbations of asthma and were over-represented in … MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary … |
View full post on asthma – Google News
 AME Info |
First asthma prevalence study results announced
AME Info A new study on the rate of asthma prevalence has found that one in eight adults across the UAE suffers from this chronic respiratory condition. The study was overseen by the Emirates Respiratory Society, conducted by leading investigators from the UAE … First Ever Asthma Prevalence Study Results Announced |
View full post on asthma – Google News
|
MediciNova To Release Asthma And COPD Trial Results In Q2
Seeking Alpha "We'll have Phase 2b results by the end of May treating patients with acute exacerbations of asthma (AEA) in the emergency room and results by June from a Phase Ib multi-dose trial in patients with moderate-to-severe chronic obstructive pulmonary … |
View full post on asthma – Google News
 Daily Mail |
Positive Results in Trial for New Asthma Treatment
news Stories Synairgen, a drug development company that spun out of the University of Southampton, United Kingdom, has announced positive results of a phase 2 clinical trial of its asthma drug SNG001. The trial investigated the potential for SNG001 to protect … Positive SNG001 Phase II Asthma Clinical Trial Data Asthma drug 'protects sufferers from life-threatening symptoms caused by … Synairgen's 'breakthrough' asthma drug shines in Phase II trial |
View full post on asthma – Google News
|
Positive results trial for new asthma treatment
Medical Xpress This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen reports positive Phase II asthma trial data Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Positive results in Southampton-led patient trial for new asthma treatment
Science Codex This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen reports positive Phase II asthma trial data Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Positive results in Southampton-led patient trial for new asthma treatment
EurekAlert (press release) This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Synairgen no wheeze as asthma drug trial boosts shares |
View full post on asthma – Google News
|
Targacept Reports Revised Top-Line Results From Phase 2 Study Of TC-6987
NASDAQ (RTTNews.com) – Targacept Inc. (TRGT) announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. After identifying an error in the application of the agreed statistical analysis plan, a reanalysis of the data … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of … Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study |
View full post on asthma – Google News
 89.3 KPCC |
Drug cost-sharing results in reduced use of necessary medications in children …
Pediatric SuperSite Health insurers' cost-sharing policies may be to blame for a dip in necessary medication use among families that have a child with asthma, according to a recent study. Pinar Karaca-Mandic, PhD, and colleagues of the Division of Health Policy and … Are Parents Price-Sensitive About Their Children's Medication? Gasping for dollars: Insurance companies take your breath away Study: Higher insurance co-pays may have serious unintended consequences for … |
View full post on asthma – Google News